6533b7dcfe1ef96bd12729d3

RESEARCH PRODUCT

Metabolic aggressiveness in benign meningiomas with chromosomal instabilities.

Miguel Cerdá-nicolásConcepción López-ginésDaniel MonleonJosé Manuel MoralesJosé M. González-darderRosario Gil-bensoA. Gonzalez-segura

subject

Cancer Researchmedicine.medical_specialtyPathologyMagnetic Resonance SpectroscopyBiologyMeningiomaChromosomal Instabilityotorhinolaryngologic diseasesmedicineMeningeal NeoplasmsTumor Cells CulturedHumansIn Situ Hybridization FluorescenceNeoplasm StagingChromosome Aberrationsmedicine.diagnostic_testCytogeneticsCancerChromosomemedicine.diseasePhenotypenervous system diseasesOncologyApoptosisBenign MeningiomaCytogenetic AnalysisMetabolomeMeningiomaFluorescence in situ hybridization

description

Abstract Meningiomas are often considered benign tumors curable by surgery, but most recurrent meningiomas correspond to histologic benign tumors. Because alterations in chromosome 14 among others have suggested clinical aggressiveness and recurrence, determining both the molecular phenotype and the genetic profile may help distinguish tumors with aggressive metabolism. The aim of this study was to achieve higher specificity in the detection of meningioma subgroups by measuring chromosomal instabilities by fluorescence in situ hybridization and cytogenetics and metabolic phenotypes by high-resolution magic angle spinning spectroscopy. We studied 46 meningioma biopsies with these methodologies. Of these, 34 were of WHO grade 1 and 12 were of WHO grade 2. Genetic analysis showed a subgroup of histologic benign meningioma with chromosomal instabilities. The metabolic phenotype of this subgroup indicated an aggressive metabolism resembling that observed for atypical meningioma. According to the metabolic profiles, these tumors had increased energy demand, higher hypoxic conditions, increased membrane turnover and cell proliferation, and possibly increased resistance to apoptosis. Taken together, our results identify distinct metabolic phenotypes for otherwise benign meningiomas based on cytogenetic studies and global metabolic profiles of intact tumors. Measuring the metabolic phenotype of meningioma intact biopsies at the same time as histopathologic analysis may allow the early detection of clinically aggressive tumors. Cancer Res; 70(21); 8426–34. ©2010 AACR.

10.1158/0008-5472.can-10-1498https://pubmed.ncbi.nlm.nih.gov/20861191